Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Troubled Biotechs (UK Edition): Summit, Alizyme, ReNeuron

This article was originally published in The Pink Sheet Daily

Executive Summary

More than a third of UK biotechs are short of cash, and those that haven’t already found creative means of monetizing their assets have run out of time.
Advertisement

Related Content

UK Government Help For Life Sciences Sector Is Welcomed, But Still Not Enough
UK Government Help For Life Sciences Sector Is Welcomed, But Still Not Enough
UK Life Sciences Package Includes "Innovation Pass" To Skirt NICE
UK Biotech Proximagen Raises Record $80 Million ‘Asset Acquisition’ Fund
Best of the Blog: IN VIVO, April 2009
NIH’s Stem Cell Guidelines To Get Dusted Off After Obama Lifts Ban
Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline
Taranabant Loss No Surprise For Obesity Field, But Shock To Merck’s Pipeline
UK Stem Cell IPOs Defy Odds
ReNeuron: Going Private

Topics

Advertisement
UsernamePublicRestriction

Register

PS069117

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel